Literature DB >> 27278502

Determinants of surgical repair of patent ductus arteriosus in low-birth-weight infants.

Yukako Yoshikane1, Toshiko Mori2, Toshiyuki Yoshizato2, Yoshihiro Miyake3, Shinichi Hirose4.   

Abstract

PURPOSE: To identify risk factors related to the failure of indomethacin therapy and the need for surgical repair in patent ductus arteriosus (PDA) in extremely low-birth-weight (<1000 g) infants (ELBWI).
METHODS: Study subjects were 36 ELBWI with PDA born at a single tertiary perinatal center. They were classified into those who required surgery due to failure of indomethacin treatment (surgical group, n = 21) and those with effective indomethacin treatment (non-surgical group, n = 15). The odds ratios (ORs) and 95% confidence intervals (95% CIs) for the relationship between selected risk factors and surgical treatment of PDA were calculated.
RESULTS: Gestational age of <28 weeks and diameter of PDA of 2 mm or more were independent and significant determinants of the need for surgical repair of PDA (adjusted ORs [95% CIs] = 9.91 [1.16-84.48] and 24.80 [2.72-225.74], respectively). The need for surgical repair of PDA did not correlate with sex, birth weight, 1-min Apgar score, left atrium diameter/aortic diameter (LA/Ao), left ventricular internal dimension at end-diastole, prophylaxes with indomethacin, and total dosage of indomethacin.
CONCLUSIONS: Gestational age at birth of <28 weeks and diameter of PDA of 2 mm or more are determinants of failure of indomethacin treatment for PDA and the need for surgical repair.

Entities:  

Keywords:  ELBWI; Gestational age; Indomethacin; PDA diameter; PDA ligation

Year:  2011        PMID: 27278502     DOI: 10.1007/s10396-011-0309-8

Source DB:  PubMed          Journal:  J Med Ultrason (2001)        ISSN: 1346-4523            Impact factor:   1.314


  14 in total

1.  Prophylactic indomethacin: factors determining permanent ductus arteriosus closure.

Authors:  M Narayanan; B Cooper; H Weiss; R I Clyman
Journal:  J Pediatr       Date:  2000-03       Impact factor: 4.406

Review 2.  Patent ductus arteriosus: pathophysiology and management.

Authors:  E R Hermes-DeSantis; R I Clyman
Journal:  J Perinatol       Date:  2006-05       Impact factor: 2.521

3.  Predictors of failed closure of patent ductus arteriosus with indomethacin.

Authors:  N Y Boo; I Mohd-Amin; A A Bilkis; F Yong-Junina
Journal:  Singapore Med J       Date:  2006-09       Impact factor: 1.858

4.  Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus.

Authors:  Christopher L Shaffer; Peter Gal; J Laurence Ransom; Rita Q Carlos; McCrae S Smith; Andrew M Davey; Mary Ann V T Dimaguila; Yvonne L Brown; Stewart A Schall
Journal:  Crit Care Med       Date:  2002-02       Impact factor: 7.598

5.  Patent ducts arteriosus in premature infants. Incidence, relation to pulmonary disease and management.

Authors:  J A Kitterman; L H Edmunds; G A Gregory; M A Heymann; W H Tooley; A M Rudolph
Journal:  N Engl J Med       Date:  1972-09-07       Impact factor: 91.245

6.  Indomethacin use for the management of patent ductus arteriosus in preterms: a web-based survey of practice attitudes among neonatal fellowship program directors in the United States.

Authors:  S B Amin; C Handley; O Carter-Pokras
Journal:  Pediatr Cardiol       Date:  2007-04-24       Impact factor: 1.655

7.  Cerebral and abdominal arterial hemodynamics in preterm infants with patent ductus arteriosus.

Authors:  K Ichihashi; H Shiraishi; H Endou; T Kuramatsu; S Yano; M Yanagisawa
Journal:  Acta Paediatr Jpn       Date:  1990-08

8.  Surgical closure of patent ductus arteriosus in preterm infants at neonatal intensive care unit.

Authors:  Chin-Te Lin; Won-Hsiung Liu; Bor-Chin Cheng; Lin-Yu Wang; Te-Jen Chen
Journal:  Acta Paediatr Taiwan       Date:  2003 Sep-Oct

9.  Analysis of outcome in 298 extremely low-birth-weight infants with patent ductus arteriosus.

Authors:  Frederick Alexander; Louisa Chiu; Matthew Kroh; Jeffrey Hammel; John Moore
Journal:  J Pediatr Surg       Date:  2009-01       Impact factor: 2.545

Review 10.  Comparative tolerability of pharmacological treatments for patent ductus arteriosus.

Authors:  C Hammerman; M Kaplan
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.